HK1205198A1 - Prediction of treatment response to jak/stat inhibitor - Google Patents

Prediction of treatment response to jak/stat inhibitor Download PDF

Info

Publication number
HK1205198A1
HK1205198A1 HK15105427.5A HK15105427A HK1205198A1 HK 1205198 A1 HK1205198 A1 HK 1205198A1 HK 15105427 A HK15105427 A HK 15105427A HK 1205198 A1 HK1205198 A1 HK 1205198A1
Authority
HK
Hong Kong
Prior art keywords
jak
prediction
stat inhibitor
treatment response
stat
Prior art date
Application number
HK15105427.5A
Other languages
English (en)
Chinese (zh)
Inventor
Alexander CAO
Michael Morrissey
Dmitriy SONKIN
Michael Palmer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1205198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1205198A1 publication Critical patent/HK1205198A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK15105427.5A 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor HK1205198A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261676484P 2012-07-27 2012-07-27
US61/676,484 2012-07-27
US201361769271P 2013-02-26 2013-02-26
US61/769,271 2013-02-26
US201361829327P 2013-05-31 2013-05-31
US61/829,327 2013-05-31
PCT/US2013/051824 WO2014018632A1 (en) 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor

Publications (1)

Publication Number Publication Date
HK1205198A1 true HK1205198A1 (en) 2015-12-11

Family

ID=48906529

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105427.5A HK1205198A1 (en) 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor

Country Status (18)

Country Link
US (1) US20150299796A1 (enExample)
EP (1) EP2877596A1 (enExample)
JP (1) JP2015526074A (enExample)
KR (1) KR20150038241A (enExample)
CN (1) CN104508149A (enExample)
AU (2) AU2013295855A1 (enExample)
BR (1) BR112015001521A2 (enExample)
CA (1) CA2880198A1 (enExample)
CL (1) CL2015000192A1 (enExample)
HK (1) HK1205198A1 (enExample)
IL (1) IL236897A0 (enExample)
MX (1) MX2015001269A (enExample)
PH (1) PH12015500169A1 (enExample)
RU (1) RU2015106714A (enExample)
SG (1) SG11201500261VA (enExample)
TN (1) TN2015000019A1 (enExample)
TW (1) TW201409030A (enExample)
WO (1) WO2014018632A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN106544414A (zh) * 2016-10-09 2017-03-29 广州泰诺迪生物科技有限公司 一种检测肺癌脑转移样本中stat3和lck的方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107137701B (zh) * 2017-05-07 2020-07-14 山东兴瑞生物科技有限公司 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US20060194275A1 (en) * 2001-04-13 2006-08-31 Incyte Corporation Transporter and ion channels
EP2350317A4 (en) * 2008-10-20 2012-06-27 Univ Colorado Regents BIOLOGICAL MARKERS FOR PREDICTING THE ANTICIPATE RESPONSE TO INSULINARY GROWTH FACTOR 1 RECEPTOR KINASE INHIBITORS
NZ597140A (en) * 2009-06-05 2014-01-31 Cephalon Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions

Also Published As

Publication number Publication date
TN2015000019A1 (en) 2016-06-29
MX2015001269A (es) 2015-05-08
AU2013295855A1 (en) 2015-02-12
KR20150038241A (ko) 2015-04-08
SG11201500261VA (en) 2015-02-27
TW201409030A (zh) 2014-03-01
CA2880198A1 (en) 2014-01-30
WO2014018632A1 (en) 2014-01-30
JP2015526074A (ja) 2015-09-10
BR112015001521A2 (pt) 2017-11-07
CL2015000192A1 (es) 2015-06-26
PH12015500169A1 (en) 2015-03-16
EP2877596A1 (en) 2015-06-03
CN104508149A (zh) 2015-04-08
AU2017204894A1 (en) 2017-08-03
US20150299796A1 (en) 2015-10-22
RU2015106714A (ru) 2016-09-20
IL236897A0 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
EP3038647A4 (en) Combination therapy for the treatment of glioblastoma
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
WO2014113089A3 (en) Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP3076977A4 (en) Combination therapy for treating cancer
NZ630542A (en) Methods of treating a tauopathy
DK3791896T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
WO2012062925A3 (en) Compounds and methods for treating pain
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP3258965A4 (en) Combination therapy for cancer treatment
WO2014151606A3 (en) Methods of treating pancreatic cancer
HK1256042A1 (zh) 用於治疗糖尿病周围神经病变的hdac抑制剂
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
LT2825558T (lt) Derinių terapija, skirta kiaušidžių vėžiui gydyti
PT3089749T (pt) Preparações combinadas para o tratamento de cancro
EP3062790A4 (en) Pharmaceutical combinations for the treatment of cancer
EP3275450A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
EP3057593A4 (en) Treatment for pancreatic cancer
EP3103446A4 (en) Pharmaceutical preparation for preventing and treating progressive myopia
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
EP3075380A4 (en) Drug for treating vertebrae cervicales and lumber diseases
EP3046556A4 (en) Combination drug therapy
WO2012106473A8 (en) Dosing for treatment with anti-egfl7 antibodies
EP3208262A4 (en) Compounds derived from 3-alkylamino-1h-indole acrylate, and the use thereof in the treatment of neurodegenerative diseases